Zosano Pharma Corporation
ZSANQ
Other OTC0.00
USD
- -
- -
CIK
0001587221
CUSIP
98979H301
Return %
Stock
S&P500
1Y
-99.93
19.01
3Y
-99.93
65.48
5Y
-99.93
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Steven Lo
- Full Time Employees
- 40
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 34790 Ardentech Court Fremont CA United States of America 94555
- CIK
- 0001587221
- Website
- zosanopharma.com
- Similar Companies
- Business
- Zosano Pharma Corporation (ZSANQ), a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Fremont, California, develops proprietary transdermal microneedle systems for the rapid systemic administration of therapeutics and bioactive molecules, including peptides, small water-soluble molecules, monoclonal antibodies, and vaccines; its lead product candidate, Qtrypta (M207), comprises a zolmitriptan formulation delivered via microneedle array for the acute treatment of migraine in patients experiencing moderate to severe headache pain, nausea, photophobia, and phonophobia. The company targets central nervous system disorders and other indications requiring fast-onset drug delivery to address unmet needs unmet by oral or injectable therapies, with operations focused in the United States. In June 2022, Zosano filed for voluntary Chapter 11 reorganization in the U.S. Bankruptcy Court for the District of Delaware to pursue restructuring amid financial challenges; by December 2022, it completed Chapter 11 liquidation proceedings and ceased operations.